Protara Therapeutics Inc (TARA)
3.71
0.00 (0.00%)
USD |
NASDAQ |
May 16, 16:00
3.71
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Cash from Financing (Quarterly): -0.076M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.076M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | -0.027M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | -0.064M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | -0.018M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -0.072M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -0.228M |
| December 31, 2020 | 10.72M |
| September 30, 2020 | 139.83M |
| June 30, 2020 | -0.371M |
| March 31, 2020 | 39.23M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.371M
Minimum
Jun 2020
139.83M
Maximum
Sep 2020
11.11M
Average
--
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| AngioDynamics Inc | 0.694M |
| Regulus Therapeutics Inc | 93.10M |
| Bio-Path Holdings Inc | 0.514M |
| Outset Medical Inc | 68.61M |
| AN2 Therapeutics Inc | 0.349M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.38M |
| Cash from Investing (Quarterly) | 23.10M |
| Free Cash Flow | -35.05M |
| Free Cash Flow Per Share (Quarterly) | -0.9088 |
| Free Cash Flow Yield | -83.16% |